Search All UT System Experts

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study

Alan N. Gordon, N. Finkler, R. P. Edwards, A. A. Garcia, M. Crozier, D. H. Irwin, E. Barrett

Research output: Contribution to journal › Article › peer-review

204 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study'. Together they form a unique fingerprint.

Medicine & Life Sciences